2BO Stock Overview
A biotechnology company, develops drugs to treat neurological diseases and pain.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Serina Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.70 |
| 52 Week High | US$11.30 |
| 52 Week Low | US$2.40 |
| Beta | 0 |
| 11 Month Change | 135.54% |
| 3 Month Change | 77.02% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2BO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.2% | -0.4% | -1.8% |
| 1Y | n/a | -15.4% | 13.6% |
Return vs Industry: Insufficient data to determine how 2BO performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2BO performed against the German Market.
Price Volatility
| 2BO volatility | |
|---|---|
| 2BO Average Weekly Movement | 78.9% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2BO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2BO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 10 | Steve Ledger | serinatherapeutics.com |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy.
Serina Therapeutics, Inc. Fundamentals Summary
| 2BO fundamental statistics | |
|---|---|
| Market cap | €55.92m |
| Earnings (TTM) | -€6.42m |
| Revenue (TTM) | €2.91m |
19.2x
P/S Ratio-8.7x
P/E RatioIs 2BO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2BO income statement (TTM) | |
|---|---|
| Revenue | US$3.17m |
| Cost of Revenue | US$4.21m |
| Gross Profit | -US$1.04m |
| Other Expenses | US$5.97m |
| Earnings | -US$7.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | -32.68% |
| Net Profit Margin | -220.87% |
| Debt/Equity Ratio | -67.9% |
How did 2BO perform over the long term?
See historical performance and comparison